Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

NCT06787482 is registered in ClinicalTrials.gov with Ace Cells Lab Limited as lead sponsor.

NCT NCT06787482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Lead sponsor
Ace Cells Lab Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2024
Completion date
December 31, 2025
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, diabetic retinopathy, retinitis pigmentosa (rp)